07.21.11
A recent study completed by Griffith University (Queensland, Australia) and the Australian Institute of Sport (Canberra, Australia) supports the health benefits of the Danisco probiotic strain Bifidobacterium lactis Bl-04 in healthy, physically active adults.
Initial results from the study were presented at the International Scientific Conference on Probiotics and Prebiotics (IPC) in Kosice, Slovakia. The study demonstrated reductions in the incidence, duration and severity of upper respiratory tract illnesses when the subjects received the probiotic B. lactis Bl-04. Chest illness severity and medication use were also reduced substantially. Professor Allan Cripps, the lead researcher on the study and Pro-Vice Chancellor at Griffith University, said, “The study provides strong evidence for the clinical efficacy of probiotics in healthy adults and is one of the first studies of its kind to do so.”
This study utilized a healthy, active target population. The trial enrolled 474 volunteers for a period of 150 days and reported reductions in upper respiratory tract illness and chest illness of 30-50%. Final analysis of the data is ongoing. For further information: www.danisco.com
Initial results from the study were presented at the International Scientific Conference on Probiotics and Prebiotics (IPC) in Kosice, Slovakia. The study demonstrated reductions in the incidence, duration and severity of upper respiratory tract illnesses when the subjects received the probiotic B. lactis Bl-04. Chest illness severity and medication use were also reduced substantially. Professor Allan Cripps, the lead researcher on the study and Pro-Vice Chancellor at Griffith University, said, “The study provides strong evidence for the clinical efficacy of probiotics in healthy adults and is one of the first studies of its kind to do so.”
This study utilized a healthy, active target population. The trial enrolled 474 volunteers for a period of 150 days and reported reductions in upper respiratory tract illness and chest illness of 30-50%. Final analysis of the data is ongoing. For further information: www.danisco.com